Highlights
- Market Cap
- $2.43B
- Enterprise Value
- $2.35B
- EPS (TTM)
- -$0.90
- Total Revenue (TTM)
- $62.38M
- Gross Profit (TTM)
- $61.20M
- EBITDA (TTM)
- -$105.54M
- Year Range
- $1.03 - $21.82
- Target Price
- $15.00
- ROA (TTM)
- -25.48%
- ROE (TTM)
- -29.35%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Tango Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Tango Therapeutics, Inc. (TNGX) has returned 136.12% so far this year and 1,427.01% over the past 12 months.
Tango Therapeutics, Inc.
- 1D
- 8.90%
- 1M
- 87.79%
- YTD
- 136.12%
- 6M
- 149.05%
- 1Y
- 1,427.01%
- 3Y*
- 74.31%
- 5Y*
- 13.76%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Sep 3, 2020, TNGX's average daily return is +0.21%, while the average monthly return is +5.16%. At this rate, your investment would double in approximately 1.1 years.
Historically, 45% of months were positive and 55% were negative. The best month was Jun 2025 with a return of +130.6%, while the worst month was Sep 2024 at -34.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, TNGX closed higher 48% of trading days. The best single day was Aug 9, 2023 with a return of +103.9%, while the worst single day was Nov 6, 2024 at -37.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 31.04% | -4.05% | 87.79% | 136.12% | |||||||||
| 2025 | -3.56% | -30.54% | -33.82% | 2.92% | 57.45% | 130.63% | 17.97% | 11.09% | 25.19% | -3.45% | 34.53% | -18.79% | 186.73% |
| 2024 | 18.69% | -5.28% | -28.66% | -3.02% | -10.13% | 23.99% | 14.80% | 20.10% | -34.91% | -29.42% | -27.51% | -21.57% | -68.79% |
| 2023 | -8.97% | -20.76% | -24.47% | -13.92% | -20.59% | 22.96% | 1.81% | 92.01% | 73.50% | -25.40% | -9.52% | 30.26% | 36.55% |
| 2022 | -22.03% | 7.39% | -17.25% | -2.90% | -9.10% | -32.29% | -9.71% | 0.24% | -11.71% | 122.10% | -6.59% | -3.46% | -33.73% |
| 2021 | -0.96% | 4.77% | -6.32% | 5.13% | -4.19% | 1.61% | -11.92% | 16.12% | 11.08% | -0.70% | -19.24% | 5.50% | -4.37% |
Benchmark Metrics
Tango Therapeutics, Inc. has an annualized alpha of 45.58%, beta of 1.14, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since September 04, 2020.
- This stock captured 130.32% of S&P 500 Index gains and 122.70% of its losses — amplifying both gains and losses, but participating more in upside than downside.
- R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 45.58%
- Beta
- 1.14
- R²
- 0.04
- Upside Capture
- 130.32%
- Downside Capture
- 122.70%
Return for Risk
Risk / Return Rank
TNGX ranks 100 for risk / return — in the top 100% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Tango Therapeutics, Inc. (TNGX) and compare them to a chosen benchmark (S&P 500 Index).
| TNGX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 12.96 | 0.90 | +12.07 |
Sortino ratioReturn per unit of downside risk | 7.03 | 1.39 | +5.64 |
Omega ratioGain probability vs. loss probability | 1.83 | 1.21 | +0.62 |
Calmar ratioReturn relative to maximum drawdown | 48.73 | 1.40 | +47.33 |
Martin ratioReturn relative to average drawdown | 136.78 | 6.61 | +130.17 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore TNGX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Tango Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Tango Therapeutics, Inc. was 93.64%, occurring on May 8, 2025. Recovery took 212 trading sessions.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -93.64% | Sep 20, 2021 | 913 | May 8, 2025 | 212 | Mar 13, 2026 | 1125 |
| -26.94% | Feb 23, 2021 | 120 | Aug 12, 2021 | 17 | Sep 7, 2021 | 137 |
| -13.43% | Jan 8, 2021 | 20 | Feb 5, 2021 | 10 | Feb 22, 2021 | 30 |
| -8% | Mar 26, 2026 | 3 | Mar 30, 2026 | 1 | Mar 31, 2026 | 4 |
| -6.07% | Sep 24, 2020 | 26 | Oct 29, 2020 | 17 | Nov 23, 2020 | 43 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Tango Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Tango Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TNGX relative to other companies in the Biotechnology industry. Currently, TNGX has a P/S ratio of 37.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TNGX in comparison with other companies in the Biotechnology industry. Currently, TNGX has a P/B value of 7.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |